AN2 Therapeutics, Inc.
HealthcareNASDAQ:ANTX · NASDAQ Global Select
+$0.29 today
Vol 0.19M · Avg 0.30M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-66.3%
avg -207.9%
ROIC
-71.6%
avg -156.6%
ROA
-56.8%
avg -163.8%
Analysis
ROA is currently the strongest return metric at -56.8% versus its period average of -163.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Eric E. Easom | Co-Founder, Chief Executive Officer, President & Chairman of the Board | $943,313.00 | — | 58 | $267,650.00 | 0.98% |
Lucy O. Day | CFO, & Principal Financial Officer | $633,580.00 | — | 66 | $0.00 | <0.01% |
Josh Eizen | Chief Legal Officer, Chief Operating Officer & Corporate Secretary | $630,000.00 | — | 47 | $92,000.00 | 0.34% |
Joseph S. Zakrzewski | Co-Founder & Independent Director | $51,500.00 | — | 64 | $99,999.00 | 0.36% |
Sanjay Chanda | Chief Development Officer | — | — | 60 | $66,000.00 | 0.24% |
Sarah Williams | Vice President of Controller & Principal Accounting Officer | — | — | 38 | $66,583.00 | 0.24% |
Michael R. K. Alley | Co-Founder, Senior Vice President of Research Fellow & Head of Biology | — | — | — | $3.22M | 11.77% |
Vince Hernandez | Senior Vice President of Research & Head of Chemistry | — | — | — | — | — |
George Harrison Talbot FACP | Co-Founder & Senior Clinical Advisor | — | — | 78 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
12
$55,291.09
Net Sentiment
$55,291.09
Net selling
Most Active
Prior Stephen David
3 transactions
1–10 of 12
Analysis
Insiders reported 0 buys worth $0.00 and 12 sells worth $55,291.09 over the last 12 months. That adds up to net selling of $55,291.09. Prior Stephen David was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Q32 Bio Inc.
NASDAQ:QTTB
$161.49M
Verrica Pharmaceuticals Inc.
NASDAQ:VRCA
$61.03M
SAB Biotherapeutics, Inc.
SABS
$31.83M
Boundless Bio, Inc.
BOLD
$31.67M
iBio, Inc.
IBIO
$26.68M
Pluri Inc.
PLUR
$20.41M
Plus Therapeutics, Inc.
PSTV
$12.12M
Intensity Therapeutics, Inc.
INTS
$6.83M
NextCure, Inc.
NXTC
$5.56M
Iterum Therapeutics plc
ITRM
$1.60M
Who manages ANTX?
AN2 Therapeutics, Inc. (ANTX) lists 9 active executives. The top listed executive is Sanjay Chanda, Chief Development Officer.
Are ANTX insiders buying or selling?
Recent insider activity shows net selling of $18.61M.
Explore More
Continue the stock analysis
Jump to another research area for this company.